Stem Cell Therapies and Treatment Advances for Heart Failure with Preserved Ejection Fraction

Monica Soni, B. Ferrell, C. Wikholm, L. Wilson
{"title":"Stem Cell Therapies and Treatment Advances for Heart Failure with Preserved Ejection Fraction","authors":"Monica Soni, B. Ferrell, C. Wikholm, L. Wilson","doi":"10.52504/001C.12344","DOIUrl":null,"url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) is characterized by a left ventricular ejection fraction of 50% or greater. While heart failure with reduced ejection fraction (HFrEF) is well-characterized and has numerous treatment options, HFpEF remains poorly understood. HFpEF has long been termed *diastolic dysfunction*, because it was thought that fibrosis and impaired relaxation of the left ventricle could alone explain the underlying pathophysiology. However, recent research has identified additional mechanisms that influence HFpEF, specifically metabolic disorders and proinflammatory conditions. Despite this recent progress in elucidating the pathophysiology, there are still no approved treatment options that increase survival in patients with HFpEF. In the context of limited pharmacological options, stem cell therapy and cardiac biomarkers have emerged as potential breakthroughs in the treatment of HFpEF, but there has not yet been a review of their potential. This review evaluates the potential of cardiosphere-derived cells (CDCs), mesenchymal stromal cells (MSCs), and endothelial progenitor cells (EPCs) in the treatment of HFpEF. CDCs have shown promise, with a placebo-controlled animal trial demonstrating an increase in survival and a marked improvement in left ventricular end diastolic filling among the group treated with intracoronary infusion of CDCs. Additionally, with the newfound understanding of HFpEF pathophysiology, studies have also investigated the role MSCs and EPCs play in the inflammation associated with HFpEF, as well as the potential benefit these stem cells would bring to the treatment of HFpEF. While clinical trials are needed to confirm the safety and efficacy of these therapies, we offer insight into their potential, as well as a comprehensive summary of the pertinent clinical studies that are currently in progress. Embase, Ovid Medline, and PubMed were used to search all relevant literature for this review.","PeriodicalId":340325,"journal":{"name":"Georgetown Medical Review","volume":"138 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Georgetown Medical Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52504/001C.12344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Heart failure with preserved ejection fraction (HFpEF) is characterized by a left ventricular ejection fraction of 50% or greater. While heart failure with reduced ejection fraction (HFrEF) is well-characterized and has numerous treatment options, HFpEF remains poorly understood. HFpEF has long been termed *diastolic dysfunction*, because it was thought that fibrosis and impaired relaxation of the left ventricle could alone explain the underlying pathophysiology. However, recent research has identified additional mechanisms that influence HFpEF, specifically metabolic disorders and proinflammatory conditions. Despite this recent progress in elucidating the pathophysiology, there are still no approved treatment options that increase survival in patients with HFpEF. In the context of limited pharmacological options, stem cell therapy and cardiac biomarkers have emerged as potential breakthroughs in the treatment of HFpEF, but there has not yet been a review of their potential. This review evaluates the potential of cardiosphere-derived cells (CDCs), mesenchymal stromal cells (MSCs), and endothelial progenitor cells (EPCs) in the treatment of HFpEF. CDCs have shown promise, with a placebo-controlled animal trial demonstrating an increase in survival and a marked improvement in left ventricular end diastolic filling among the group treated with intracoronary infusion of CDCs. Additionally, with the newfound understanding of HFpEF pathophysiology, studies have also investigated the role MSCs and EPCs play in the inflammation associated with HFpEF, as well as the potential benefit these stem cells would bring to the treatment of HFpEF. While clinical trials are needed to confirm the safety and efficacy of these therapies, we offer insight into their potential, as well as a comprehensive summary of the pertinent clinical studies that are currently in progress. Embase, Ovid Medline, and PubMed were used to search all relevant literature for this review.
保留射血分数的心力衰竭的干细胞治疗和治疗进展
保留射血分数(HFpEF)心力衰竭的特征是左心室射血分数大于或等于50%。虽然心力衰竭伴射血分数降低(HFrEF)具有很好的特征,并且有许多治疗选择,但HFpEF仍然知之甚少。HFpEF长期以来被称为“舒张功能障碍”,因为人们认为纤维化和左心室舒张受损可以单独解释潜在的病理生理。然而,最近的研究已经确定了影响HFpEF的其他机制,特别是代谢紊乱和促炎条件。尽管最近在阐明病理生理学方面取得了进展,但仍然没有批准的治疗方案可以提高HFpEF患者的生存率。在有限的药理学选择的背景下,干细胞疗法和心脏生物标志物已成为HFpEF治疗的潜在突破,但尚未对其潜力进行审查。本综述评估了心球源性细胞(cdc)、间充质基质细胞(MSCs)和内皮祖细胞(EPCs)在HFpEF治疗中的潜力。cdc显示出了希望,一项安慰剂对照动物试验表明,在冠状动脉内输注cdc的组中,生存率增加,左心室舒张末期充盈明显改善。此外,随着对HFpEF病理生理学的新认识,研究还研究了MSCs和EPCs在HFpEF相关炎症中的作用,以及这些干细胞对HFpEF治疗的潜在益处。虽然需要临床试验来确认这些疗法的安全性和有效性,但我们提供了对其潜力的见解,以及目前正在进行的相关临床研究的全面总结。使用Embase、Ovid Medline和PubMed检索本综述的所有相关文献。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信